CEO & INVESTOR CONFERENCE

February 10-11, 2020 • New York, NY
New York Marriott Marquis

#BIOCEO20 • bio.org/CEO
Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies.

Event Attributes and Opportunities

- **Experience the best of biotech** with two-days of productive partnering meetings with institutional investors, industry analysts, and senior biotechnology executives, in one location.
- **Hear Washington’s perspective on policy** and other timely developments affecting the industry.
- **Evaluate fresh investment opportunities** including compatible, complementary, and competitive companies.
- **Learn about the hottest clinical developments** and industry catalysts by attending the conference’s therapeutic and business-focused panel discussions.
- **Attend fireside chats with senior business leaders** who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2020.
- **Gain access to BIO One-on-One Partnering™** for scouting potential investments and deal partners, optimizing your time at the event.
- **Unique platform for your company** to highlight accomplishments and discuss upcoming milestones. Approximately 170 companies will be chosen based on a selection process evaluating a company’s pipeline and R&D activities.
- **Get the pulse** of the current and proposed investment trends in biotechnology.
- **Network with peers, investors, and potential partners** attending the conference and our exclusive receptions.
- **Exclusive sponsorship opportunities** to showcase thought leadership, elevate brand identity and maximize partnering benefits with an elite audience.

1,200+ ATTENDEES

2,900+ PARTNERING MEETINGS

133 COMPANY PRESENTATIONS

650 REGISTERED INVESTORS

948 PARTICIPATING COMPANIES

33 COUNTRIES REPRESENTED

#BIOCEO20 • bio.org/CEO
2019 Advisory Committee

Each year, BIO assembles a group of industry thought leaders to help us shape the conference program and provide input on key topics and themes that deliver excellence for all attendees.
With an Air of Optimism, #BIOCEO19 Concludes
A record number of investors—over 660—registered to learn about the latest biotech trends and to search for opportunities to turn technology into life-saving treatments. More than 130 biotechnology and pharmaceutical companies delivered 13-minute pitches showcasing their pipeline, R&D activities, business objectives and investment goals. Information was also shared through face-to-face meetings scheduled by the BIO One-on-One Partnering system which was in full swing, scheduling almost 3,000 meetings—a record for this 21st annual event.

Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical Innovation?
In his State of the Union address, President Trump called on Congress to “do more” to lower drug costs in the United States. Already, the U.S. Department of Health and Human Services (HHS) has proposed piloting an International Pricing Index payment model, tying costs for drugs under Medicare Part B to the lower rates paid in European benchmark countries with socialized medicine. They have moved to lower government costs for drug spending by empowering PBMs and middlemen to dramatically expand the use of utilization management tools like “fail first” that deny patients access to needed medicines. And most recently, HHS proposed changes to the drug rebate system with the goal of eliminating perverse incentives to inflate a drug’s list price. Following a year with a record number of new medicines being approved by the FDA, such reforms introduce significant uncertainty for biotech investors. The Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical Innovation? session explores the impact these moves have on biomedical investment and innovation.

Venture Creation is in Vogue
In the biotech industry, it’s common for a company to raise billions of dollars and wait more than a dozen years before their investors see a return. That’s why capital formation can be an arduous journey in the biotech industry. But the biotech IPO market is coming off of a hot 2018 with more than 50 biotech companies going public on the back of more than $5.4 billion in funding, marking the second-best year for biotech IPOs in a decade.

Market Outlook—Leveraging Market Corrections for M&A or IPOs
After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year of heightened market volatility. Investors’ eagerness to support new modalities enabled more than 50 biotech IPOs, but with much less mature clinical development progress than traditionally demonstrated. More than half those companies are trading below their IPO prices, however, complicating conditions for the next new offering. As interest rate worries, international trade disputes, and regulatory reimbursement uncertainty have increased, biopharma stock indexes have seen significant corrections. With historically high valuations experiencing sudden dips, M&A deal-making seems to have reignited with notable, multi-billion dollar deals in recent weeks. The Market Outlook—Leveraging Market Corrections for M&A or IPOs session brought together market experts to discuss what forces continue to shape performance within the sector and what opportunities the market correction can reveal for investors and companies seeking resources to deliver the next wave of innovative therapies for patients.

#BIOCEO19: Navigating Payers’ Expectations for Value-Based Agreements
Value-based agreements are becoming increasingly important in the biopharmaceutical reimbursement space, particularly as new advanced therapeutic modalities and prospective cures for diseases which previously had no comparable treatments enter the market. Yet the departure from more traditional volume-based reimbursement models poses unique difficulties for biopharmaceutical companies, payers, patients, providers, and investors in planning for a new therapy’s rollout and the breadth of patient access to it. This evolving landscape was the subject of a lively and informative discussion on the first day of the 2019 BIO CEO and Investor Conference.

Education and Conference Programming
BIO’s business and therapeutic panel discussions, plus Fireside Chats with biopharma leaders, provide insights on issues essential to the industry and provide a wealth of information of strategic relevance to help your organization succeed.
Partnering

BIO One-on-One Partnering is the most efficient way to do business in the biotech and pharma industry without traveling all over the world. Our system makes it easy to search for and identify potential partners and request meetings with prospective biotech investors and senior business development executives.

Representative Program Speakers
- Aoife Brennan, MD, CHB, Chief Executive Officer and Chief Medical Officer, Synlogic, Inc.
- Brian K. Kaspar, PhD, Chief Scientific Officer, AveXis
- Ciara Kennedy, PhD, President and Chief Executive Officer, Amplyx
- Geoff Meyerson, Managing Partner and Co-Founder, Locust Walk
- Ron Philip, Chief Commercial Officer, Spark Therapeutics
- Nancy Thornberry, Chief Executive Officer, Kallyope
- Philip Ross, Vice Chairman, J.P. Morgan
- William Slattery, Partner, Deerfield
- Erica Whittaker, PhD, Head of UCB Ventures, UCB Pharma
- Lynn O’Connor Vos, President and CEO, Muscular Dystrophy Association

Representative Companies
- Ascletis Pharma
- Alnylam Pharmaceuticals
- Celgene
- Daré Bioscience
- MaxCyte
- Mitsubishi Tanabe Pharma
- Neurotrope
- Redhill Biopharma
- Sanofi
- Vyriad

Full Program ➤  Full Company List ➤
Investor Engagement

With an industry that is rapidly and dynamically shifting, the BIO CEO & Investor Conference is a perfect balance of educational content that help investors stay attuned to issues that are relevant to peers and current/future clients while also providing an exclusive venue to source new frontiers in discovery and ensure high-quality interactions between corporate and investor colleagues.

2019 Participating Investors

- Bridge Bank
- Brookline Capital Group
- Brookline Capital Markets
- Brothers & Partners Europe
- Bryan, Garnier & Co
- BTG
- Diageo Advisors
- Cato BioVentures
- Catox Alternative Management LP
- CB Capital
- C-Bridge Capital
- CEC Capital Group
- Cederus Investments
- Charter Bank Capital
- Charlotte Capital
- Chronus Capital
- CJ Hageman & Co.
- Cowen and Company
- Cowen Healthcare Investments
- Crown Capital
- Crown Point Group
- CRR
- CS McKee
- CSC Leasing
- CTT Life Sciences
- CTTQ Pharmaceutical Group
- Dabar Investment Associates
- Deco Family Ventures
- Deca Ventures
- Debas Capital Partners/Debas Life Sciences
- Deloitte
- DHVC
- Diamondback Capital Management
- Douglas O. Lake & Associates
- Dynamic Capital
- E Squared Capital Management, LLC
- East Coast Capital
- Efiat Investments
- Enform Bio
- Essexia Holdings
- Everyone Capital
- EVOLUTION Life Sciences Partners
- Fannie Innovation Studio
- FC Capital Management
- Fiera Capital
- First Island Capital
- Foresee Capital Management
- Fortress Biotech
- Fortuna Capital
- Fonon Pharma
- Forfith Asset Management
- GDF Family Office
- GE Ventures
- Genoa Ventures
- GSIQ Capital
- Global Corporate Finance
- Global Health Investment Fund
- Global Source Ventures
- Golden Seeds
- Goldwater Asset Management
- Good Health Capital
- Gorlin Companies
- Gradus/JSU Private Equity
- GreenSky Capital
- Grey Bio Venture Partners
- Griffin Securities
- Guggenheim
- H.C. Warth & Company
- H2C Bio-Health Partners
- HjL Capital
- Harbin Pharmaceutical Group
- HarvardBio Capital
- Hartford Financial Management
- Hayfin Capital Management
- HCM Healthcare Royalty Partners
- Helicas Ventures
- Helm Management
- Herrera Ventures
- Hercules Capital
- H I Investors Capital
- Hood River Capital Management
- Hudson East Capital
- Humanawed Healthcare Group
- Iaco Ventures
- IDG Capital Partners
- Ilumina Ventures
- Image Analysis Group
- INKEF Capital
- InPharmaceuticals
- Janello Ventures
- Johnson Associates
- J.P. Morgan
- Kaka Fund LP
- Katalyst Securities
- Knoll Capital Management
- L I Capital
- L2 Capital
- Ladborg Thalmann
- Laidlaw & Company
- Landmark Angels
- LifeBio Equity Partners
- LifeTech Capital
- Lilly Asia Ventures
- Lincoln Park Capital
- Livingston
- Loctust Walk
- Long Island
- Lord Abbott
- LS Works
- Lumina Capital
- Madison Square Capital
- Magid Family Office
- MaxArm Capital
- Maxum Merchant Capital
- May Tech Global Investments
- MAC Capital Advisors
- Medisence Ventures
- Medventures
- MEV Ventures Group
- Meren Nexus
- Mid Atlantic Bio Angels
- Milia Hill Ventures
- Mitral Capital Management
- Mitsui & Co. Global Investment
- Mizuho Bank
- Mizuho Securities
- Momentum Biotech
- Montrose Capital Partners
- Movacor Capital
- MP Healthcare Venture Management
- MPM Capital
- MIRAB Capital
- MSK Ventures
- Murfied Capital
- Muro Capital
- Muro Capital Partners
- Corporation
- NVP Investments
- National Cancer Institute
- Neurimmune
- New Harbor Ventures
- New Science Ventures
- New York City Economic Development Corporation
- NQ Capital
- NJ Angels
- Noble E. Survey
- Jong Capital
- Northen Light Venture Capital
- Norwood Management
- North Capital
- NTP Capital
- NYC Innovation VC Fund
- Occidental Ventures
- NPG Capital
- Nile Capital
- NY National Innovation VC Fund
- Odyssey Capital
- Oppenheimer & Co
- Opti Capital Management
- Orchard View Capital Advisors LP
- Orkin Consultants Financiers
- Ortho Pharmaceutical Co.
- Oxford Finance
- Pappas Capital
- Park Ave. Capital Management
- International
- Pauion Investment Company
- Peak One Investments
- Peter S. Gerdes & Co.
- Perrichon Healthcare Capital Management
- Pfizer
- Pharmaxon Advisors
- Pipette Angels
- Pipette Capital
- Pipo & Jeffrey Ventures
- Power Gate
- Provail Partners
- Princeton Biopharma
- Prometheus Capital Group
- Qiming Venture Partners
- Quan Capital
- Radius Financial
- Redbank Healthcare Management
- Remsen Investors LP
- Repertoire Asset Management
- RHK Capital
- Rokin
- ROTH Capital Partners
- Royal Pharma Management
- Santeon Pharmaceuticals Co.
- Saranoff Investments
- Satter Medical Technology Partners
- SBF Management
- SC Fundamental
- Scopus Ventures
- Second Line Capital Management
- Seroba Life Sciences
- Serra Capital
- Shanghai Fosun Pharmaceutical Group Co.
- Sharp Strategic Capital
- Shenzhen Salubris Pharmaceuticals
- Cobi
- Simex Advisors
- Sio Capital/Management
- Sofinnova Ventures
- Somero Therapeutics
- Sonoma Life Sciences
- Source Capital
- Speculative Investments
- Special Situations Funds
- Square 1 Bank
- StarLink Capital
- Strata Angel Ventures
- SunTrust Robinson Humphrey
- Surveyor Capital
- SV Investment
- Symphonia Partners
- Taglich Private Equity
- Talium Investments
- Tanaka Capital Management
- Tap Advisors
- Terra Magnum Capital Partners
- The Anson Group
- The Schapiro Group
- The Schapiro Group
- The Schapiro Group
- The Mark Foundation for Cancer Research
- TransPacific Venture Capital Partners
- Trevor Capital
- Trigon Capital Partners
- Turner Capital Management
- Urkam Capital
- Upstream Ventures
- V2 Life Sciences Fund
- Vector Research Funds
- Versant Ventures
- Viva Ventures
- VivaBioholdings
- Viva Capital
- W Global Capital Ltd/International Capital Management
- Watermill Capital
- Watermill Asset Management
- WBB Asset Management
- WBB Securities, LLC
- Wells Fargo
- Wespark Capital
- Westpark Capital
- Whittall Partners
- Wolf Capital Management
- WindNorth Associates
- Xeraya Capital
- Life Venture
- Yas Global
- Yale University
- YLG Management Services
- Yujin Capital
- Zukunft Capital
- Zacks ICR
- Zarey Holdings New York

#BIOCEO20 • bio.org/CEO
Company Presentations

Opportunity for biotechnology and pharmaceutical companies to do 13-minute pitches showcasing their pipeline, R&D activities, business objectives and investment goals. Presenting companies are hand-selected for the event and consist of mid-to large-cap established public companies, and select private companies, from around the globe.

2019 PRESENTING COMPANIES

**Cardiovascular**
Espero BioPharma
InCarda Therapeutics
Rerverlogix Corp.
Verseon

**CNS/Neurological**
Anavex Life Sciences
Bioasis Technologies Inc.
BioXcel Therapeutics
Cox Biosciences LLC
E-Scan Bio
EIP Pharma, Inc.
Knopp Biosciences
NeuroRx
Newron Pharmaceuticals SpA
NeXO Inc.
ORYZON
Otsuka Pharmaceutical
PAION AG
Serina Therapeutics, Inc.
Tonix Pharmaceuticals Holding Corp.
Trevena, Inc.
Valon Pharmaceuticals
ViataGen Therapeutics, Inc.
Zynerba Pharmaceuticals

**Dermatology**
Azitra Inc.

**Diagnostics**
BioMarker Strategies, LLC
Genes2me LLP
Interpace Diagnostics
OncoCyte

**Digital Health**
Congenica Ltd
Lumme Inc

**Gastrointestinal**
Cancer Prevention Pharmaceuticals
Landos Biopharma
Mirum Pharmaceuticals
Synthetic Biologics, Inc.

**Gene/Cell Therapy**
American Gene Technologies
Brainstorm Cell Therapeutics
Cesca Therapeutics Inc.
Eloxx Pharmaceuticals
Fibrocell Science, Inc.
MeiraGTx

**Immunology**
Abcro, Inc.
aTyr Pharma, Inc.
INMune Bio
Immun AG
ImmuneSYS, Inc.

**Infectious Diseases**
Amgen Pharmaceuticals Inc.
CyoDyn Inc.
Summit Therapeutics
VenatoRx Pharmaceuticals

**Medical Devices**
Arch Therapeutics, Inc.
CryoSorbents
Femeda Ltd

**Metabolic Diseases**
CohBar, Inc.
SERAXIS INC.

**Multiple Therapeutics**
Aryllam Pharmaceuticals
LifeEDIT
Lyndra Inc
Q BioMed Inc
Sirnaomics,Inc

**Non-Profit/Patient Advocacy Group**
National Health Council Patient-Centered Health Care Accelerator

**Oncology**
Actinium Pharmaceuticals, Inc.
AIVITA Biomedical
AUM Biosciences
CASI Pharmaceuticals, Inc.
CEL-SCI Corporation
Cellcentric Biosciences
Cue Biopharma
Curis, Inc
Cyclacel Pharmaceuticals, Inc.
Exicure
Greenwich LifeSciences
Heat Biologics, Inc.
Immunicum AB
ImmunoMet Therapeutics
Immunomedic, Inc.
IMV Inc.
Infinity Pharmaceuticals
Kleo Pharmaceuticals
MaxCyte, Inc.
OncoVere Biotech Inc.
Onconova Therapeutics, Inc.
OxSonics Limited
Propanc Biopharma Inc.

**Salaries Pharmaceuticals**
Sapiience Therapeutics
SATOR Therapeutics LLC
SELLAS Life Sciences Group, Inc.
Sent BioSciences
Stuto Biopharma, Inc.
Tarveda Therapeutics, Inc
Trovagene Oncology
Vyradi, Inc.
Zenith Epigenetics

**Ophthalmology**
EyeGate Pharmaceuticals, Inc.
Nemus Biosciences
Nicox SA
OcuMedic
Oxilon NV
Oyster Point Pharma, Inc.

**Orphan/Rare Diseases**
Arcturus Therapeutics
Catalyst Biosciences
Catalyst Pharmaceuticals, Inc.
Children’s Tumor Foundation
Fulcrum Therapeutics
Lung Therapeutics

**Other**
Rockwell Medical, Inc
Select Greater Philadelphia

**Platform for Therapeutics**
Anima Biotech Inc.
Aqueative Therapeutics
Oramed Pharmaceuticals
Second Genome, Inc

**Regenerative Medicine**
Aspect Biosystems
Caladrius Biosciences, Inc
Carmell Therapeutics
SpinalCyte, LLC

**Reproductive/Sexual Health**
Daré Bioscience
Urigen Pharmaceuticals, Inc.

**Respiratory**
ProterixBio, Inc
Tenax Therapeutics, Inc.
Verona Pharma

**Tools/Drug Development Support Tech**
AbMax Biotechnology CO., LTD
Precision NanoSystems

2019 BUZZ of BIO Winners

PUBLIC THERAPEUTIC BIOTECH

PRIVATE THERAPEUTIC BIOTECH

DIAGNOSTICS AND BEYOND
2019 Sponsors

DOUBLE HELIX SPONSORS

- Bristol-Myers Squibb
- Lilly

SUPPORTING BANK SPONSORS

- Alliance Global Partners
- BMO Falcon
- HCW
- ROTH Capital Partners

CONFERENCE SPONSORS

- AlphaSense
- Aon
- Blaise Group International
- CHUBB
- CNS
- FreeMind
- Immunoprecise
- Locust Walk
- MarCum
- Morrison Foerster
- NDA
- Nucleus Network
- proactive investors
- Servier
- Share Vault
- Syneos Health
- The Money Channel
- Torreya
- VWR

LOCAL CO-HOST

NEW YORK BIO
## 2020 Sponsorship Opportunities

<table>
<thead>
<tr>
<th>Showcase Thought Leadership</th>
<th>Number of Registrations</th>
<th>Recognition on Conference Website, Materials and Signage</th>
<th>Advertisement in Conference Program</th>
<th>Access to BIO One-on-One Partnering</th>
<th>Partnering Suite and Priority Scheduling of Meetings</th>
<th>Guaranteed Speaking Opportunity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Program Sponsor</strong></td>
<td>3</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Company Presentations Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Access Your Target Audience</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Welcome Reception Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hospitality Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Closing Reception Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tabletop Exhibit Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Maximize Partnering &amp; Deal Making</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BIO One-on-One Partnering System Sponsor</strong></td>
<td>3</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Partnering Suite Package</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Partnering Lounge Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Boost Brand Visibility</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Conference Bag Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lanyard Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Conference Program Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>WiFi Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Buzz of BIO Contest Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Social Media Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Luggage and Coat Check Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Charging Station Sponsor</strong></td>
<td>1</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hotel Key Card Sponsor</strong></td>
<td>1</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Good Day BIO Sponsor</strong></td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Print &amp; Digital Advertising</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Digital Daily Email Sponsor</strong></td>
<td>1</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Conference Program Advertisement</strong></td>
<td>0</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Digital Advertising</strong></td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>High Visibility Signage</strong></td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

► Our Sales & Sponsorship team is always ready to support your event engagement. Please feel free to reach out to the team at +1.202.312.9264 or sponsor@bio.org.